Movatterモバイル変換

[0]ホーム

Jump to content

Vantictumab

Edit links

From Wikipedia, the free encyclopedia

Monoclonal antibody

Pharmaceutical compound

Vantictumab
Monoclonal antibody
Type	?
Source	Human
Target	Frizzled receptor
Clinical data
Routes of administration	IV
ATC code	none
Identifiers
CAS Number	1345009-45-1
ChemSpider	none
UNII	88WBI2D80S
KEGG	D10410
Chemical and physical data
Formula	C₆₃₂₂H₉₇₂₂N₁₆₇₄O₁₉₈₈S₄₆
Molar mass	142461.81 g·mol⁻¹

Vantictumab/vænˈtɪktʊmæb/ is a human IgG2monoclonal antibody designed for the treatment ofcancer.^[1]

This drug was developed byOncoMed Pharmaceuticals Inc. in partnership withBayer.^[2] OncoMed was awarded a patent in 2016, which is set to expire in 2029.^[3] In April 2017, Bayer terminated its option to license vantictumab.^[4]

It inhibitswnt signalling by targeting thefrizzled receptors on cancer cells.^[5]

Phase I trials have been completed forpancreatic cancer,non-small cell lung cancer, andbreast cancer. In 2016 results were reported from a phase 1b clinical trial fortriple-negative breast cancer^[5]^[6] and in 2020 for pancreatic cancer.^[7]

References

[edit]

^"Statement on a nonproprietary name adopted by the USAN Council"(PDF).AMA. 28 Nov 2012. N12/155.(registration required)
^"OncoMed Pre-Announces 2014 Year-End Cash Balance and Provides 2015 Guidance" (Press release). 12 January 2015.
^"Annual Report on Form 10-K". OncoMed Pharmaceuticals, Inc. Archived fromthe original on 13 January 2017.
^"BRIEF-Oncomed Pharmaceuticals announces Bayer terminates its option to license vantictumab or ipafricept".Reuters. 10 April 2017.
^^a ^b"Finally, targeted therapies for triple-negative breast cancer".Medical Xpress. June 2016.
^Diamond JR, Becerra C, Richards D, Mita A, Osborne C, O'Shaughnessy J, et al. (November 2020)."Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer".Breast Cancer Research and Treatment.184 (1):53–62.doi:10.1007/s10549-020-05817-w.PMC 7572714.PMID 32803633.
^Davis SL, Cardin DB, Shahda S, Lenz HJ, Dotan E, O'Neil BH, et al. (June 2020)."A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer".Investigational New Drugs.38 (3):821–830.doi:10.1007/s10637-019-00824-1.PMC 7211194.PMID 31338636.

Monoclonal antibodies for tumors

Tumor

Human	Adecatumumab^§ Amivantamab (+hyaluronidase) Ascrinvacumab^§ Balstilimab^† Botensilimab Cixutumumab^§ Conatumumab^§ Cosibelimab Daratumumab Drozitumab^§ Duligotumab^§ Dusigitumab^§ Enfortumab vedotin Enoticumab^§ Figitumumab^§ Flanvotumab^§ Ganitumab^† Glembatumumab vedotin^† Intetumumab^§ Ipilimumab Iratumumab^§ Istiratumab Icrucumab^§ Lexatumumab^§ Linvoseltamab Lucatumumab^§ Mapatumumab^§ Narnatumab^§ Necitumumab Nesvacumab^§ Nivolumab^# (+hyaluronidase,+relatlimab) Ofatumumab Olaratumab^† Panitumumab Patritumab^§ Pritumumab^§ Radretumab^§ Ramucirumab Rilotumumab^† Robatumumab^§ Seribantumab^§ Sugemalimab Tarextumab^§ Tisotumab vedotin Teprotumumab^† Tovetumab^§ Vantictumab^§ Votumumab^§ Zalutumumab^†
Mouse	Abagovomab Altumomab pentetate Anatumomab mafenatox Arcitumomab Bectumomab Blinatumomab Capromab pendetide Detumomab Edrecolomab Ibritumomab tiuxetan Igovomab Lilotomab Minretumomab Mitumomab Nacolomab tafenatox Moxetumomab pasudotox Naptumomab estafenatox Oregovomab Pemtumomab^† Racotumomab Satumomab pendetide Solitomab Taplitumomab paptox Nofetumomab merpentan Pintumomab Tenatumomab Tositumomab
Chimeric	Amatuximab^§ Bavituximab^§ Brentuximab vedotin Carotuximab^† Cetuximab Derlotuximab biotin^§ Dinutuximab Ecromeximab^§ Ensituximab^§ Futuximab^§ Girentuximab^† Indatuximab ravtansine^§ Isatuximab Loncastuximab tesirine Margetuximab Mirvetuximab soravtansine Rituximab^# Siltuximab Ublituximab Zolbetuximab
Humanized	Abituzumab^§ Alemtuzumab Atezolizumab (+hyaluronidase) Axatilimab Belantamab mafodotin Bevacizumab Bivatuzumab mertansine^§ Brontictuzumab^§ Cantuzumab mertansine^§ Cantuzumab ravtansine^§ Cirmtuzumab Citatuzumab bogatox^§ Clivatuzumab tetraxetan Cofetuzumab pelidotin Dacetuzumab^§ Demcizumab^§ Dalotuzumab^§ Datopotamab deruxtecan Denintuzumab mafodotin^§ Elotuzumab Emactuzumab Emibetuzumab^§ Enoblituzumab^§ Epcoritamab Etaracizumab^§ Farletuzumab^§ Ficlatuzumab^§ Flotetuzumab^§ Gemtuzumab ozogamicin Glofitamab Imgatuzumab^§ Inotuzumab ozogamicin Labetuzumab^§ Lifastuzumab vedotin^§ Lintuzumab^§ Lorvotuzumab mertansine^§ Lumretuzumab^§ Matuzumab^§ Milatuzumab^§ Naxitamab Nimotuzumab^† Obinutuzumab Ocaratuzumab^§ Odronextamab Otlertuzumab^§ Onartuzumab^§ Oportuzumab monatox^† Parsatuzumab^§ Pembrolizumab^# (+berahyaluronidase alfa) Penpulimab Pertuzumab Pinatuzumab vedotin^§ Polatuzumab vedotin Rosmantuzumab Rovalpituzumab tesirine^† Sacituzumab govitecan Sibrotuzumab^§ Simtuzumab^§ Sofituzumab vedotin^§ Tacatuzumab tetraxetan^§ Tigatuzumab^§ Trastuzumab^# (+deruxtecan /+emtansine) Tucotuzumab celmoleukin^§ Vandortuzumab vedotin^§ Vanucizumab^§ Veltuzumab^§ Vorsetuzumab mafodotin^§ Zenocutuzumab
Rat/mouse hybrid	Catumaxomab Ertumaxomab^§
Chimeric + humanized	Depatuxizumab mafodotin^† Duvortuxizumab Ontuxizumab^§

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

Thismonoclonal antibody–related article is astub. You can help Wikipedia byadding missing information.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Vantictumab&oldid=1211701089"

Categories:

Hidden categories:

[8]ページ先頭